Tilmicosin ELISA Kit

Name: Tilmicosin ELISA Kit
SKU: DEIA038
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Animal tissue, liver, honey, egg, milk

Detection Method

cELISA

Intended Use

This kit can be used in quantitative and qualitative analysis of tilmicosin residue in animal tissue, liver, honey, egg, milk.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Microtiter plate	96 wells coated with antigen	2-8°C
2	Standard solutions	6×1ml/bottle: 0ppb, 0.5ppb,1.5ppb, 4.5ppb,13.5ppb,40.5ppb	2-8°C
3	Spiking standard solution	1ml/bottle 1ppm	2-8°C
4	Enzyme conjugate	7ml	2-8°C
5	Antibody solution	7ml	2-8°C
6	Substrate solution A	7ml	2-8°C
7	Substrate solution B	7ml	2-8°C
8	Stop solution	7ml	2-8°C
9	20×concentrated wash solution	40ml	2-8°C
10	4×Concentrated extraction solution	50ml	2-8°C

Storage

Storage condition: 2-8°C.
Storage period: 12 months.

Performance Characteristics

Accuracy
High detection limit tissue: 90±20%
Low detection limit tissue: 90±20%
Liver (chicken liver, pork liver): 75±15%
Honey: 95±25%
Egg, Milk: 95±25%

Precision

Variation coefficient of the ELISA kit is less than 10%.

Detection Limit

High detection limit tissue: 0.5ppb
Low detection limit tissue: 10ppb
Liver (chicken liver, pork liver): 10ppb
Honey: 1ppb
Egg, Milk: 5ppb

Sensitivity

0.5ppb

General Description

Tilmicosin is mainly used to against the bacterial and mycoplasma infection in livestock and poultry. It is also used to the additive of the feed of pig to promote the weight of the pig and the feed conversion rate.
This kit is a new product for drug residue detection based on ELISA technology, which can considerably minimize operation errors and work intensity compared with instrumental analysis. It only needs 45min.

Citations

Have you cited DEIA038 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Q & A

Ask a Question

Q: Does the U.S. Food and Drug Administration (FDA) have regulations on the residue limit of Tilmicosin? Can you provide the residue limit in ppb and the corresponding reference materials?

A: The FDA has not set a clear residue limit (MRL) for Tilmicosin. However, according to European regulations and the Turkish Food Code, the maximum residue limit for Tilmicosin in beef is 75 μg/kg and the maximum residue limit in pork is 50 μg/kg. (μg/kg = 1 ppb (parts per billion) = 1 microgram of element per kilogram)

Customer Reviews

References

Clinical effectiveness of tulathromycin, a novel triamilide antimicrobial, for the control of respiratory disease in cattle at high risk for developing bovine respiratory disease

VETERINARY THERAPEUTICS

Authors: Kilgore, WR; Nutsch, RG; Spensley, MS; Rooney, KA; Sun, FS; Skogerboe, TL

Abstract

The efficacy of tulathromycin in decreasing the incidence of morbidity and mortality due to bovine respiratory disease (BRD) in 1,239 high-risk cattle was investigated at four US feedlots. Calves not exhibiting clinical signs of BRD received one of three treatments administered SC in the neck: physiologic saline at 0.02 ml/kg, tulathromycin at 2.5 mg/kg, or tilmicosin at 10 mg/kg. Each treatment group consisted of 413 calves. Calves with clinical signs of BRD and rectal temperatures of 104 degrees F or higher on any day through day 14 were considered treatment failures (BRD morbidity). Nasopharyngeal swabs from saline-treated morbidities were submitted for isolation and identification of BIRD organisms. Respiratory disease morbidity was highest in calves treated with saline and significantly (P <= .0001) lower in calves that received tulathromycin or tilmicosin. Morbidity from BRD was significantly (P <= .0001) higher in calves treated with tilmicosin than in calves treated with tulathromycin. Under conditions of this study, tulathromycin given to calves at high risk of developing BRD was significantly more effective in reducing BRD morbidity compared with both saline and tilmicosin.

Efficacy of tulathromycin versus enrofloxacin for initial treatment of naturally occurring bovine respiratory disease in feeder calves

VETERINARY THERAPEUTICS

Authors: Robb, Edward J.; Tucker, Cassius M.; Corley, Lane; Bryson, W. Lawrence; Rogers, Karen C.; Sturgess, Kynan; Bade, Donald J.; Brodersen, Bruce

Abstract

After undergoing arrival processing at one of two commercial feedlots, feeder calves with clinical signs of bovine respiratory disease (BRD) were randomly assigned to receive either tulathromycin (2.5 mg/kg SC) or enrofloxacin (12.5 mg/kg SC). Additional the apy for calves that did not respond to initial treatment followed a prescribed course. Initial treatment with tulathromycin resulted in significantly higher (P =.009 and P = 031 at sites 1 and 2, respectively) therapeutic success (87.9% and 80%, respectively) than did initial treatment with enrofloxacin (70.2% and 62.5%, respectively). Animals treated with tulathromycin also had fewer subsequent treatments and higher weight gains compared with those treated with enrofloxacin.